Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals
NCT ID: NCT06934473
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
16 participants
INTERVENTIONAL
2025-05-21
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension
NCT06208904
GIP Receptor Antagonist Studies in Humans
NCT02747472
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
NCT06426823
Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
NCT00999271
Physiology of GIP(1-30)NH2 in Humans
NCT04792762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GIP(3-30)NH2 + mixed meal test
Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min + mixed meal test
GIP(3-30)NH2 / study tool
Selective antagonist of the GIPR, GIP(3-30)NH2
Saline (NaCl 0,9 %) (placebo)
Placebo (NaCl 0,9%)
Saline + mixed meal test
Intravenous infusion of saline 9 mg/ml added 0.5% human serum albumin + mixed meal test
GIP(3-30)NH2 / study tool
Selective antagonist of the GIPR, GIP(3-30)NH2
Saline (NaCl 0,9 %) (placebo)
Placebo (NaCl 0,9%)
GIP(1-42) + water
Intravenous infusion of GIP(1-42) in a concentration of 4,000 pmol/kg/min + intake of water
GIP(1-42)
Agonist of the GIPR, GIP(1-42)
Saline + water
Intravenous infusion of saline 9 mg/ml added 0.5% human serum albumin + intake of water
Saline (NaCl 0,9 %) (placebo)
Placebo (NaCl 0,9%)
GIP(1-42)
Agonist of the GIPR, GIP(1-42)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP(3-30)NH2 / study tool
Selective antagonist of the GIPR, GIP(3-30)NH2
Saline (NaCl 0,9 %) (placebo)
Placebo (NaCl 0,9%)
GIP(1-42)
Agonist of the GIPR, GIP(1-42)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI between 18.5 and 29.9 kg/m2 (both included)
3. Informed consent
Exclusion Criteria
2. History of Orthostatic Hypotension (OH) or Postural Orthostatic Tachycardia Syndrome (POTS) or other autonomic dysfunction at the discretion of the investigators
3. Anaemia (haemoglobin below normal range \<7.3 mmol/L for women and \<8.3 mmol/L for men)
4. Kidney disease (estimated glomerular filtration rate (eGFR) \<90 ml/min/1.73 m2) at screening
5. Known liver disease and/or elevated plasma alanine aminotransferase (ALT) \> three times the upper limit of normal at screening
6. Treatment with antihypertensives
7. Treatment with GLP-1RA (Glucagon-like Peptide-1 Receptor Agonist)
8. Treatment with SNRI (Serotonin and Noradrenalin Reuptake Inhibitor) or treatment within two weeks before the first experimental day
9. Any ongoing medication that the investigator evaluates would interfere with trial participation
10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation, including any acute or chronic illnesses
11. Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardize the participant's safety during the trial
12. Alcohol/drug abuse as per discretion of the investigators
13. Pregnancy or breastfeeding
14. Participation in any other clinical trial during the study period
15. Mental incapacity or language barriers that preclude adequate understanding or cooperation or unwillingness to comply with trial requirements or pr discretion of the investigator
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
lise wilki-kurtzhals
MD, PhD student
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GA-25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.